Conway Kevin John 4

4 · Generation Bio Co. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Generation Bio (GBIO) CFO Kevin Conway Converts 235 RSUs, 72 Withheld

What Happened

Kevin J. Conway, Chief Financial Officer of Generation Bio (GBIO), had 235 restricted stock units convert into 235 shares on Feb 2, 2026 (reported on a Form 4 filed Feb 4, 2026). No cash exercise price was paid (reported $0.00).
To cover tax withholding, 72 of the newly issued shares were withheld and disposed of at a reported per-share withholding value of $5.64, producing proceeds of $406.

Key Details

Transaction dates: conversion/vesting and withholding occurred on 2026-02-02; Form 4 filed 2026-02-04. This appears timely (Form 4s are due within two business days).
Prices/values: conversion reported at $0.00 (derivative conversion); tax withholding: 72 shares @ $5.64 = $406.
Shares owned after transaction: not specified in the provided excerpt of the filing.
Footnotes: F1 clarifies each restricted stock unit (RSU) represents one share. F2 notes a grant of 9,390 RSUs on Jan 20, 2023 vested in full on Feb 2, 2026 under the Merger Agreement; Conway’s filing shows 235 RSUs converted.
Transaction codes: M = exercise/conversion of derivative (here, RSU conversion); F = shares withheld to satisfy tax withholding.

Context

This was a conversion/vesting event (not a cash purchase or open-market sale). The withholding of shares to cover taxes is a routine administrative step and does not by itself indicate buying or selling sentiment. The accelerated vesting is tied to the Merger Agreement referenced in the footnote.

Form 4

Period: 2026-02-02

CHIEF FINANCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-02+235→ 2,144 total
Tax Payment
Common Stock
2026-02-02$5.64/sh−72$406→ 2,072 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-02-02−235→ 0 total
→ Common Stock (235 underlying)

Footnotes (2)

[F1]Each restricted stock unit represents the right to receive one share of the company's common stock.
[F2]2. The grant of 9,390 restricted stock units was made on January 20, 2023. Pursuant to the terms of that certain Agreement and Plan of Merger, by and among the Issuer, XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp., dated as of December 15, 2025 (the "Merger Agreement"), prior to the effective time of the merger as contemplated by the Merger Agreement, each restricted stock unit of the Issuer that was outstanding and unvested became vested in full on February 2, 2026.

Signature

/s/ Shawna-Gay White, Attorney-in-Fact|2026-02-04

1 file